Dentium (KRX:145720) Seems To Use Debt Quite Sensibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We note that Dentium CO., LTD (KRX:145720) does have debt on its balance sheet. But should shareholders be worried about its use of debt?

Advertisement

When Is Debt A Problem?

Debt is a tool to help businesses grow, but if a business is incapable of paying off its lenders, then it exists at their mercy. If things get really bad, the lenders can take control of the business. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

See our latest analysis for Dentium

What Is Dentium's Net Debt?

As you can see below, Dentium had ₩215.5b of debt, at March 2024, which is about the same as the year before. You can click the chart for greater detail. However, because it has a cash reserve of ₩88.7b, its net debt is less, at about ₩126.8b.

debt-equity-history-analysis
KOSE:A145720 Debt to Equity History July 5th 2024

A Look At Dentium's Liabilities

We can see from the most recent balance sheet that Dentium had liabilities of ₩266.8b falling due within a year, and liabilities of ₩51.8b due beyond that. Offsetting this, it had ₩88.7b in cash and ₩141.3b in receivables that were due within 12 months. So it has liabilities totalling ₩88.6b more than its cash and near-term receivables, combined.

Since publicly traded Dentium shares are worth a total of ₩942.6b, it seems unlikely that this level of liabilities would be a major threat. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse.

In order to size up a company's debt relative to its earnings, we calculate its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and its earnings before interest and tax (EBIT) divided by its interest expense (its interest cover). This way, we consider both the absolute quantum of the debt, as well as the interest rates paid on it.

Dentium's net debt is only 0.82 times its EBITDA. And its EBIT covers its interest expense a whopping 22.7 times over. So we're pretty relaxed about its super-conservative use of debt. The good news is that Dentium has increased its EBIT by 5.6% over twelve months, which should ease any concerns about debt repayment. When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Dentium's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. So it's worth checking how much of that EBIT is backed by free cash flow. Over the last three years, Dentium reported free cash flow worth 18% of its EBIT, which is really quite low. That limp level of cash conversion undermines its ability to manage and pay down debt.

Our View

Happily, Dentium's impressive interest cover implies it has the upper hand on its debt. But truth be told we feel its conversion of EBIT to free cash flow does undermine this impression a bit. We would also note that Medical Equipment industry companies like Dentium commonly do use debt without problems. Looking at all the aforementioned factors together, it strikes us that Dentium can handle its debt fairly comfortably. On the plus side, this leverage can boost shareholder returns, but the potential downside is more risk of loss, so it's worth monitoring the balance sheet. Over time, share prices tend to follow earnings per share, so if you're interested in Dentium, you may well want to click here to check an interactive graph of its earnings per share history.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About KOSE:A145720

Dentium

Manufactures and sells dental medical instrument worldwide.

Very undervalued with excellent balance sheet.

Advertisement

Weekly Picks

CE
Ceazar
GOAI logo
Ceazar on Eva Live ·

This small cap is building the AI workforce of the future

Fair Value:US$7.4352.8% undervalued
69 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
TR
tripledub
LULU logo
tripledub on lululemon athletica ·

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Fair Value:US$22045.8% undervalued
16 users have followed this narrative
4 users have commented on this narrative
21 users have liked this narrative
WO
woodworthfund
KHC logo
woodworthfund on Kraft Heinz ·

Kraft Heinz (KHC): Less Drama, More Ketchup

Fair Value:US$3533.5% undervalued
6 users have followed this narrative
0 users have commented on this narrative
2 users have liked this narrative
CA
Canderous
TAL logo
Canderous on PetroTal ·

Beyond 2026, Beyond a Double

Fair Value:CA$1.8168.5% undervalued
21 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

KA
kapirey
KSPI logo
kapirey on Kaspi.kz ·

Kaspi.kz represents a high-quality, high-growth fintech/e-commerce platform

Fair Value:US$99.029.4% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
FTAI logo
kapirey on FTAI Aviation ·

Attractive if you believe in prolonged engine shortages and slow fleet renewal

Fair Value:US$225.050.7% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
ARGX logo
kapirey on argenx ·

High-growth biotech compounding story if VYVGART becomes a multi-indication platform drug

Fair Value:€686.430.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8591.4% undervalued
114 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74018.6% undervalued
39 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$268.6117.9% undervalued
1186 users have followed this narrative
7 users have commented on this narrative
34 users have liked this narrative